5.31
0.21 (4.12%)
Penutupan Terdahulu | 5.10 |
Buka | 5.26 |
Jumlah Dagangan | 1,896,178 |
Purata Dagangan (3B) | 2,962,593 |
Modal Pasaran | 480,769,024 |
Harga / Pendapatan (P/E Ke hadapan) | 10.04 |
Harga / Jualan (P/S) | 0.260 |
Harga / Buku (P/B) | 1.19 |
Julat 52 Minggu | |
Tarikh Pendapatan | 11 Aug 2025 - 15 Aug 2025 |
Margin Keuntungan | -29.43% |
Margin Operasi (TTM) | -3.81% |
EPS Cair (TTM) | -8.39 |
Pertumbuhan Hasil Suku Tahunan (YOY) | -1.60% |
Jumlah Hutang/Ekuiti (D/E MRQ) | 149.92% |
Nisbah Semasa (MRQ) | 0.970 |
Aliran Tunai Operasi (OCF TTM) | 164.20 M |
Aliran Tunai Bebas Leveraj (LFCF TTM) | 310.66 M |
Pulangan Atas Aset (ROA TTM) | -1.74% |
Pulangan Atas Ekuiti (ROE TTM) | -61.58% |
Arah Aliran Pasaran
Jangka Pendek | Jangka Sederhana | ||
Industri | Biotechnology (US) | Bercampur | Menurun |
Biotechnology (Global) | Bercampur | Menurun | |
Stok | Fortrea Holdings Inc. | Menaik | Menurun |
AISkor Stockmoo
Konsensus Penganalisis | 3.0 |
Aktiviti Orang Dalam | 3.0 |
Volatiliti Harga | 0.5 |
Purata Bergerak Teknikal | 0.0 |
Osilator Teknikal | 2.0 |
Purata | 1.70 |
Fortrea Holdings is a late-stage contract research organization, or CRO, that provides comprehensive Phase I through IV clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries. |
|
Sektor | Healthcare |
Industri | Biotechnology |
Gaya Pelaburan | Small Value |
% Dimiliki oleh Orang Dalam | 0.40% |
% Dimiliki oleh Institusi | 101.90% |
Julat 52 Minggu | ||
Julat Harga Sasaran | ||
Tinggi | 9.00 (Baird, 69.49%) | Beli |
Median | 7.00 (31.83%) | |
Rendah | 6.00 (Barclays, 12.99%) | Jual |
Purata | 7.25 (36.54%) | |
Jumlah | 1 Beli, 2 Pegang, 1 Jual | |
Harga Purata @ Panggilan | 6.34 |
Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
---|---|---|---|---|
Evercore ISI Group | 08 Aug 2025 | 7.00 (31.83%) | Pegang | 6.58 |
09 Jul 2025 | 5.00 (-5.84%) | Pegang | 5.04 | |
Barclays | 07 Aug 2025 | 6.00 (12.99%) | Jual | 7.24 |
Baird | 04 Aug 2025 | 9.00 (69.49%) | Beli | 6.42 |
Mizuho | 11 Jul 2025 | 7.00 (31.83%) | Pegang | 5.11 |
Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
---|---|---|---|---|
MCCONNELL JILL G. | - | 7.89 | -4,886 | -38,551 |
MORAIS MARK A. | - | 7.89 | -4,886 | -38,551 |
NEUPERT PETER M | 6.49 | - | 62,500 | 405,075 |
Jumlah Keseluruhan Kuantiti Bersih | 52,728 | |||
Jumlah Keseluruhan Nilai Bersih ($) | 327,974 | |||
Purata Pembelian Keseluruhan ($) | 6.49 | |||
Purata Jualan Keseluruhan ($) | 7.89 | |||
Julat Insider ($) |
Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
---|---|---|---|---|---|---|
MCCONNELL JILL G. | Pegawai | 19 Aug 2025 | Jual (-) | 4,886 | 7.89 | 38,551 |
MORAIS MARK A. | Pegawai | 19 Aug 2025 | Jual (-) | 4,886 | 7.89 | 38,551 |
MCCONNELL JILL G. | Pegawai | 18 Aug 2025 | Pelaksanaan pilihan | 11,312 | - | - |
MORAIS MARK A. | Pegawai | 18 Aug 2025 | Pelaksanaan pilihan | 11,312 | - | - |
NEUPERT PETER M | Pengarah | 11 Aug 2025 | Beli (+) | 32,500 | 6.39 | 207,675 |
NEUPERT PETER M | Pengarah | 08 Aug 2025 | Beli (+) | 30,000 | 6.58 | 197,400 |
Tarikh | Jenis | Butiran |
---|---|---|
06 Aug 2025 | Pengumuman | Fortrea Reports Second Quarter 2025 Results |
05 Aug 2025 | Pengumuman | Fortrea Appoints Tracy Krumme as Senior Vice President, Investor Relations |
04 Aug 2025 | Pengumuman | Fortrea Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) |
16 Jul 2025 | Pengumuman | Fortrea Announces Date for Second Quarter 2025 Financial Results and Conference Call |
24 Jun 2025 | Pengumuman | Fortrea & Emery Pharma Announce Strategic Collaboration to Deliver FDA Compliant Drug-Drug-Interaction Studies Using Rifampin |
12 Jun 2025 | Pengumuman | Fortrea Adopts Limited-Duration Stockholder Rights Plan |
11 Jun 2025 | Pengumuman | Fortrea Names Anshul Thakral Chief Executive Officer |
03 Jun 2025 | Pengumuman | Fortrea to Present at the Jefferies Global Healthcare Conference |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
Keuntungan Nyata | - |
Keuntungan Tidak Nyata | - |
Dividen Diterima 2025 | - |
Jumlah Untung | - |
Pulangan Purata | - |
Kuantiti (Beli) | - |
Purata Harga (Beli) | - |
Kuantiti (Jual) | - |
Purata Harga (Jual) | - |